Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants

McMaster University

$60,000.00

New Covalent Antibody Anchoring Technology To Develop Novel Target Tunable, Multispecific Chemical Tumor Immunotherapeutics.

EF 2018-19

Résumé
Our project is focused on creating a new class of cancer therapeutics that use small synthetic molecules to accumulate high numbers of naturally occuring antibodies to the site of solid tumors. These antibodies activate immune cells to eliminate the tumor enabling for a higher more durable anti-tumor killing response. These molecules we call "covalent antibody recruiting molecules or cARMs" differ from conventional antibody therapeutics in that they are much easier to produce and avoid the need for the IV administration of large doses of expensive antibodies. As such, our synthetic cARM approach should enable for much more general patient accessible cancer treatments. Importantly, cARMs should maintain the high tumor targeting selectivity and low off-target side effects associated with antibody immunotherapeutics with the additional advantage of being able to rapidly develop cARMs against a wide range of different tumor types. cARMs can also be uniquely designed to generate multispecific tumor targeting antibodies which are difficult to create.
Programme
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
407429
Name
Rullo Anthony F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
New Covalent Antibody Anchoring Technology To Develop Novel Target Tunable, Multispecific Chemical Tumor Immunotherapeutics.
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Cancer
Abstract
Our project is focused on creating a new class of cancer therapeutics that use small synthetic molecules to accumulate high numbers of naturally occuring antibodies to the site of solid tumors. These antibodies activate immune cells to eliminate the tumor enabling for a higher more durable anti-tumor killing response. These molecules we call "covalent antibody recruiting molecules or cARMs" differ from conventional antibody therapeutics in that they are much easier to produce and avoid the need for the IV administration of large doses of expensive antibodies. As such, our synthetic cARM approach should enable for much more general patient accessible cancer treatments. Importantly, cARMs should maintain the high tumor targeting selectivity and low off-target side effects associated with antibody immunotherapeutics with the additional advantage of being able to rapidly develop cARMs against a wide range of different tumor types. cARMs can also be uniquely designed to generate multispecific tumor targeting antibodies which are difficult to create.
Competitiondate
201902
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Rullo, Anthony F
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Cancer Research~ $60,000~ $0~